Embecta faces class action after Q2 2026 miss, dividend cut and stock plunge

Embecta Corp. and certain senior executives are facing a securities class action tied to alleged misstatements during the Nov. 25, 2025 to May 4, 2026 period about the resilience of the company’s insulin pen needle business. According to the complaint, later filed in the U.S. District Court for the District of New Jersey as Apitz-Grossman v. Embecta Corp., et al., No. 26-cv-07217, the company reassured investors about stable insulin pen demand and reaffirmed fiscal 2026 adjusted EPS guidance of $2.80 to $3.00 on Feb. 5, 2026, while maintaining its dividend plans, despite alleged competition, share loss and broader softness in insulin pen and pen needle demand. On May 5, 2026, Embecta reported Q2 2026 adjusted EPS of $0.27, disclosed pen needle share loss tied mostly to a single customer and retail-channel volume weakness, cut 2026 adjusted EPS guidance to $1.55 to $1.75, and reduced its quarterly dividend to $0.01 from $0.15. The stock fell 57.8% that day, and investors have until Aug. 17, 2026 to seek appointment as lead plaintiff.